⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S3 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy

Yifan Liu Hongying Wang Xinyu Zhao Jiashen Zhang Zhiling Zhao Xia Lian Juan Zhang Feng Kong Tao Hu Ting Wang Xiaohua Li Lei Wang Dapeng Wang Chunling Li Huiwen Luan Xiaoli Liu Chunyan Wang Yun Jiang Xiaomin Li Fangmin Li Shuhao Ji Yaopeng Wang Zunling Li

View Full Paper

Ask AI

Bookmark

Share

Abstract

Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523c48 https://doi.org/10.1158/0008-5472.27028786

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
2Figure S1 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
3Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
4Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
5Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024